Stay updated with breaking news from Matthewl posard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […] ....
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […] ....
Hsbc Holdings PLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 63.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,904 shares of the biopharmaceutical company’s stock after acquiring an additional 32,118 shares during the quarter. Hsbc […] ....
Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 11.1% during the second quarter, Holdings Channel reports. The institutional investor owned 16,734 shares of the biopharmaceutical company’s stock after selling 2,085 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Halozyme Therapeutics were worth $736,000 […] ....